• Print
  • Download PDF

Babesia microti IgG IFA

Test Code: 95325

Cpt Code:

86753 (x1)

Clinical Utility

Babesia microti IgG and IgM assays are used to detect infection of the tick-borne protozoan Babesia microti, specifically in cases of diagnostic uncertainty or suspected chronic infection. The assays are performed by indirect fluorescent antibody (IFA) methods. Titer values above the reference intervals are considered evidence of current (IgG or IgM) or past (IgG) infection.


Human IgG antibody to Babesia microti (B. microti) antigens are detected by indirect fluorescent antibody (IFA) assay. Briefly, a slide well coated with fixed, infected red blood cells are incubated with diluted human serum. If specific
B. microti
antibodies are present, they remain bound, are then labeled by an antibody conjugate and finally detected by fluorescence microscopy.


Sera from patients shown to have been infected by other tick-borne pathogens, Babesia duncani, Rickettsia rickettsii and Borrelia burgdorferi, were screened and found negative by the B. microti IgG IFA.

Assay Range

1:64 - 1:1,024 titer.

Causes For Rejection

Specimens beyond their acceptable length of time from collection as listed in the specimen handling, or specimen types other than those listed.

Turnaround Time

1-5 days from receipt of specimen. Assay performed Monday and Thursday.


Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor-IBT test requisition form must accompany each specimen. Ship specimens FedEx Priority Overnight to: Viracor-IBT Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086.

Specimen Information


NY approved. Collect 4-5 mL whole blood in red top tube, centrifuge and transfer 2 mL serum to sterile, screw top tube (minimum volume 0.05 mL). Can be shipped at ambient or frozen temperature Monday through Friday. Specimens shipped at ambient temperature must be received within 96 hrs of collection.


Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

The CPT codes provided are based on Viracor-IBT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor-IBT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.


Krause PJ, Telford III SR, Ryan R, Conrad PA, Wilson M, Thomford JW and Spielman A. Diagnosis of Babesiosis: Evaluation of a Serologic Test for the Detection of Babesia microti Antibody. 1994. J of Inf Dis. 169, 923-926.

Krause PJ, Ryan R, Telford III SR, Persing D and Spielman A. Efficacy of Immunoglobulin M Serodiagnostic Test for Rapid Diagnosis of Acute Babesiosis. 1996. J of Clin Microbiol. 34 (8), 2014-2016.

Mayne PJ. Emerging incidence of Lyme borreliosis, babesiosis, bartonellosis, and granulocytic ehrlichiosis in Australia. Int J Gen Med. 2011, 4, 845-852.

US CDC web site. http://www.cdc.gov/parasites/babesiosis/. Accessed April 2, 2014.

Simonsen KA, Harwell JI and Lainwala S. Clinical presentation and treatment of transfusion-associated babesiosis in premature infants. Pediatrics. 2011. 128(4):e1019-1024.

Vannier E, Gewruz BE, Krause PJ. Human Babesiosis. Inf Dis Clin of N Am. 2008, 22, 269-288.


<< Back to list